Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Prognostic markers under watchful waiting and radical prostatectomy.

Holmberg L, Bill-Axelson A, Garmo H, Palmgren J, Norlén BJ, Adami HO, Johansson JE; SPCG-4 Study Group.

Hematol Oncol Clin North Am. 2006 Aug;20(4):845-55. Review.

PMID:
16861118
2.

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.

Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.

Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23.

PMID:
18783735
3.

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4.

J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54. doi: 10.1093/jnci/djn255. Epub 2008 Aug 11.

4.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
5.

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.

Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson JE, Steineck G; Scandinavian Prostate Cancer Group Study No 4.

Eur Urol. 2009 Feb;55(2):422-30. doi: 10.1016/j.eururo.2008.08.054. Epub 2008 Sep 2.

PMID:
18783877
6.

Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.

Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, Shariat SF, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS.

Urol Oncol. 2007 Jul-Aug;25(4):291-7.

PMID:
17628294
7.

Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.

Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, Yu CC, Wu TT, Huang CH, Wu WJ, Chou YH, Wu MT.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6632-8.

8.

Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.

Villamón-Fort R, Martínez-Jabaloyas JM, Soriano-Sarriá P, Ramos-Soler D, Pastor-Hernández F, Gil-Salom M.

Urol Int. 2007;78(4):328-33.

PMID:
17495491
9.

Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.

Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.

Eur Urol. 2008 Jul;54(1):118-25. doi: 10.1016/j.eururo.2008.02.018. Epub 2008 Feb 26.

PMID:
18314255
10.

The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.

Kositsawat J, Flanigan RC, Meydani M, Choi YK, Freeman VL.

J Urol. 2007 Dec;178(6):2391-6; discussion 2396. Epub 2007 Oct 22.

PMID:
17936811
11.

Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.

May M, Siegsmund M, Hammermann F, Loy V, Gunia S.

Scand J Urol Nephrol. 2007;41(5):375-81. Epub 2007 Jul 27.

PMID:
17853019
12.

Should we replace the Gleason score with the amount of high-grade prostate cancer?

Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.

Eur Urol. 2007 Apr;51(4):931-9. Epub 2006 Aug 15.

PMID:
16935413
13.

Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer.

Liu L, Coker AL, Du XL, Cormier JN, Ford CE, Fang S.

J Surg Oncol. 2008 Jun 1;97(7):583-91. doi: 10.1002/jso.21028.

PMID:
18381603
14.

Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.

King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr.

Urology. 2007 May;69(5):921-6.

PMID:
17482935
15.

Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.

Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-7.

16.

Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.

Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ.

Urol Oncol. 2006 Nov-Dec;24(6):465-71.

PMID:
17138126
17.
18.

Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.

May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.

J Urol. 2007 Nov;178(5):1957-62; discussion 1962. Epub 2007 Sep 17.

PMID:
17868719
19.

Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.

D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.

J Urol. 2006 Dec;176(6 Pt 2):S11-5.

PMID:
17084157
20.

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.

Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.

J Urol. 2007 Sep;178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16.

PMID:
17631342

Supplemental Content

Support Center